Mohua Das is a Scientist at the A*STAR Genome Institute of Singapore, where she is working at the forefront of drug discovery and precision oncology. She holds a PhD degree in medicinal chemistry from the National University of Singapore. Her research bridges the gap between chemical design and genomic insights to tackle cancer, particularly by identifying transcriptomic signatures of drug resistance and developing novel inhibitors for colorectal cancer.
Das’s research leadership is backed by a track record of competitive grant acquisitions, including the NMRC Open Fund-IRG. Most notably, her recent design of β-catenin inhibitors has moved into the patent-pending stage, signalling a significant leap in targeted therapy development. Beyond her technical expertise, Das is an influential mentor to over 20 junior scientists and is passionate about integrating data science into traditional pharmaceutical curriculum using her expertise.
